MedTrace Logo

Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)

NCT06559072 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 522

Last updated 2024-09-05

No results posted yet for this study

Summary

A researcher-initiated and conducted multicenter, randomized controlled trial aimed at evaluating the efficacy and safety of ultra-early statin therapy in the treatment of acute aneurysmal subarachnoid hemorrhage (aSAH).

Conditions

  • Subarachnoid Hemorrhage
  • Subarachnoid Hemorrhage, Aneurysmal
  • Aneurysmal Subarachnoid Hemorrhage
  • Hemorrhage, Aneurysmal Subarachnoid

Interventions

DRUG

Atorvastatin

On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • The George Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2026-01-01
Completion
2026-09-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06559072 on ClinicalTrials.gov